Inovio reports positive interim phase 1/2 results for ino-3107 for the treatment of recurrent respiratory papillomatosis

Treatment with ino-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial ino-3107 demonstrated statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year ino-3107 was found to be well-tolerated and immunogenic plymouth meeting, pa. , oct. 13, 2022 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and prevent infectious diseases, cancer, and diseases associated with hpv, today announced positive interim results from an ongoing phase 1/2 clinical trial evaluating ino-3107 for the treatment of hpv 6 and hpv 11-associated recurrent respiratory papillomatosis (rrp) in adults.
INO Ratings Summary
INO Quant Ranking